Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants

SIMPLE SUMMARY: In our study, we retrospectively collected data of patients with germline CDKN2A pathogenic variants who received targeted therapy for advanced melanoma across four European centers. Since loss of CDKN2A function may intrinsically limit the activity of MAPK-directed targeted therapy,...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancers (Basel)
Hlavní autoři: Spagnolo, Francesco, Dalmasso, Bruna, Tanda, Enrica, Potrony, Miriam, Puig, Susana, van Doorn, Remco, Kapiteijn, Ellen, Queirolo, Paola, Helgadottir, Hildur, Ghiorzo, Paola
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2021
Témata:
Communication
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8157545/
https://ncbi.nlm.nih.gov/pubmed/34069952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13102440
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky